Focused On-demand Library for Mitochondrial ribonuclease P catalytic subunit

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O15091

UPID:

MRPP3_HUMAN

Alternative names:

Mitochondrial ribonuclease P protein 3; Protein only RNase P catalytic subunit

Alternative UPACC:

O15091; B4DXD9; B4E0S8; B4E211; C4AM93; D3DS99; D3DSA1; Q86SZ4; Q86YB5; Q8N5L5

Background:

The Mitochondrial ribonuclease P catalytic subunit, also known as Protein only RNase P catalytic subunit, plays a pivotal role in mitochondrial RNA processing. It is a key component of the mitochondrial ribonuclease P complex, essential for cleaving tRNA molecules at their 5'-ends, a critical step in the maturation of mitochondrial tRNAs. This protein's function underscores its importance in mitochondrial transcription and translation, processes vital for cellular energy production.

Therapeutic significance:

Combined oxidative phosphorylation deficiency 54, a multisystem disorder with variable manifestations including sensorineural hearing loss and muscle weakness, is linked to mutations affecting this protein. Understanding the role of the Mitochondrial ribonuclease P catalytic subunit could open doors to potential therapeutic strategies for this and related mitochondrial disorders.